Lineage Cell Therapeutics, Inc. LCTX
- Market cap
- $239.7M
- P/E
- 0.0×
Follow LCTX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.77 | 1.84 | 0.66 | 0.53 | 0.58 | 1.55 | 1.02 | 0.90 | 0.48 | 0.37 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 3.51 | 3.32 | 2.76 | 1.73 | 2.01 | 3.13 | 2.58 | 1.58 | 1.61 | 2.09 |
High Price
|
|||
| 102 | 95 | 79 | 55 | 55 | 61 | 78 | 75 | 77 | 77 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 6 | 3 | 5 | 4 | 2 | 4 | 15 | 9 | 9 | 15 |
Revenue
|
|||
| 93.96% | 95.14% | 93.95% | 88.28% | 78.92% | 67.15% | 95.05% | 92.50% | 96.48% | 99.00% |
Gross Margin
|
|||
| 19 | (23) | (47) | (19) | (22) | (43) | (26) | (23) | (19) | (69) |
EBT
|
|||
| 314.38% | (673.48%) | (944.87%) | (547.20%) | (1,200.66%) | (996.77%) | (175.56%) | (260.28%) | (195.62%) | (471.61%) |
EBT Margin
|
|||
| 34 | (20) | (46) | (12) | (21) | (43) | (26) | (21) | (19) | (63) |
Net Income
|
|||
| 5 | 4 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 15 |
Depreciation
|
|||
| 0.06 | 0.03 | 0.04 | 0.02 | 0.01 | 0.03 | 0.09 | 0.05 | 0.05 | 0.06 |
Revenue/Sh
|
|||
| 0.35 | (0.17) | (0.36) | (0.08) | (0.14) | (0.26) | (0.15) | (0.12) | (0.09) | (0.28) |
Earnings/Sh
|
|||
| (0.43) | (0.27) | (0.24) | (0.22) | (0.13) | (0.14) | 0.01 | (0.17) | (0.12) | (0.08) |
Cash Flow/Sh
|
|||
| (0.03) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.46) | (0.28) | (0.25) | (0.22) | (0.13) | (0.15) | 0.00 | (0.17) | (0.12) | (0.08) |
Free CF/Sh
|
|||
| 1.34 | 1.43 | 0.73 | 0.76 | 0.63 | 0.55 | 0.42 | 0.36 | 0.38 | 0.19 |
Book Value/Sh
|
|||
| 97 | 114 | 127 | 146 | 150 | 165 | 170 | 173 | 200 | 230 |
Shares
|
|||
| 10.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 52.25 | 66.21 | 23.15 | 36.85 | 144.62 | 92.84 | 14.20 | 21.04 | 10.54 | 26.40 |
PS Ratio
|
|||
| 2.37 | 1.39 | 1.25 | 1.16 | 2.78 | 4.43 | 2.90 | 3.03 | 1.30 | 8.87 |
PB Ratio
|
|||
| 48.66 | 55.21 | 17.01 | 28.13 | 121.87 | 79.41 | 10.27 | 17.08 | 5.51 | 22.57 |
EV/Sales
|
|||
| (6.43) | (6.03) | (2.63) | (3.06) | (11.24) | (14.42) | 233.83 | (5.23) | (2.21) | (16.90) |
EV/FCF
|
|||
| (42) | (31) | (31) | (32) | (20) | (24) | 1 | (29) | (23) | (19) |
Op' Cash Flow
|
|||
| (3) | (1) | (1) | 0 | 0 | 0 | 0 | (1) | (1) | (1) |
Capex
|
|||
| (45) | (32) | (32) | (32) | (20) | (24) | 1 | (29) | (24) | (19) |
FCF
|
|||
| 17 | 36 | 30 | 51 | 36 | 64 | 41 | 20 | 37 | 48 |
Working Cap'
|
|||
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Debt
|
|||
| (21) | (38) | (31) | (31) | (42) | (58) | (58) | (35) | (48) | (56) |
Net Debt
|
|||
| 131 | 164 | 92 | 111 | 95 | 91 | 72 | 62 | 77 | 43 |
Sh' Equity
|
|||
| 28.30% | (12.65%) | (33.46%) | (10.31%) | (17.69%) | (30.46%) | (17.62%) | (19.13%) | (17.37%) | (56.27%) |
ROA
|
|||
| (33.73%) | (19.26%) | (42.40%) | (30.14%) | (30.84%) | (94.43%) | (99.51%) | (58.07%) | (45.86%) | 0.00% |
ROIC
|
|||
| 32.44% | (13.55%) | (35.86%) | (11.51%) | (20.01%) | (46.25%) | (32.27%) | (32.08%) | (26.77%) | (105.57%) |
ROE
|
|||
Lineage Cell Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CUE Cue Biopharma, Inc. | $238.6M | 0.0× | Compare |
| CAMP CAMP4 Therapeutics Corporation | $241.0M | 0.0× | Compare |
| NAGE Niagen Bioscience, Inc. | $238.2M | 15.2× | Compare |
| SION Sionna Therapeutics, Inc. | $241.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MGNX MacroGenics, Inc. | $242.1M | 0.0× | Compare |
| TRDA Entrada Therapeutics, Inc. | $242.2M | 0.0× | Compare |
| PRQR ProQR Therapeutics N.V. | $236.1M | 0.0× | Compare |
| YARW Yarrow Bioscience, Inc | $246.0M | 0.0× | Compare |
Lineage Cell Therapeutics, Inc. (LCTX) key facts
- Lineage Cell Therapeutics, Inc. (LCTX) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- Lineage Cell Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.6 million, up 53.2% from fiscal 2024.
- Lineage Cell Therapeutics, Inc. reported a net loss of $63.4 million, or a loss of $0.28 per share, for fiscal 2025.
- As of September 25, 2026, LCTX traded at $1.03, a market capitalization of $239.7 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 19.6× sales.
- Return on equity was −105.6% and debt-to-equity 0.00.
Lineage Cell Therapeutics, Inc. (LCTX) Latest News
8 Sep
Lineage Cell Therapeutics, Inc. (LCTX) announces issuance of a patent for its AlloSCOPE™ 5D Manufacturing Platform. Patent issuance bolsters IP protection for core manufacturing technology with moderate effect on competitive positioning.
13 Aug
Lineage Cell Therapeutics held its Q2 2026 earnings call covering financial results, operational updates and future outlook. Earnings call provides standard financial and operational details that may affect short-term sentiment without major strategic shifts.
9 Aug
Lineage Cell Therapeutics reported Q2 financial results and provided pipeline updates during its earnings call, covering operational progress and cash position. Q2 earnings call delivers standard financial metrics and operational updates that may moderately affect near-term market sentiment without major strategic shifts.
7 Aug
Lineage Cell Therapeutics, Inc. released its Q2 2026 earnings call summary covering financial results, operational updates and future outlook. Quarterly earnings updates can moderately influence near-term sentiment and valuation for LCTX without altering long-term trajectory.
Lineage Cell Therapeutics extended its cash runway per Q2 2026 earnings call highlights. Extended cash runway provides operational support but does not alter core trajectory.
6 Aug
Lineage Cell Therapeutics reported second quarter 2026 financial results and provided a business update. Quarterly results and updates typically produce moderate effects on company valuation and sentiment.
14 Jul
Lineage Cell Therapeutics advances COR1 cell therapy via a 'thaw and inject' plan to simplify administration and map the clinical path forward. Thaw-and-inject formulation for COR1 enables operational streamlining and wider clinical use without altering core company trajectory.
13 Jul
Lineage Cell Therapeutics provides an update on its COR1 cell therapy program for corneal endothelial disease. COR1 program update could affect LCTX development pipeline and market position in cell therapies.
4 Jun
New data releases and updated analyst price targets are shifting the outlook and investor positioning for Lineage Cell Therapeutics (LCTX). New data and analyst target revisions can influence near-term sentiment and valuation but rarely alter long-term company trajectory by themselves.
15 May
Lineage Cell Therapeutics reported Q1 results with updates on clinical pipeline progress, cash position, and development timelines for cell therapies targeting ophthalmology and neurology indications. Q1 earnings provide pipeline and cash runway details that moderately influence near-term investor sentiment without altering long-term company trajectory.
13 May
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 earnings call highlights strategic advances amid ongoing developments. Strategic advances highlighted in Q1 2026 earnings call represent major moves likely to significantly influence LCTX's trajectory and investor sentiment.
Lineage Cell Therapeutics, Inc. released Q1 2026 earnings results and operational updates during its earnings call. Quarterly earnings and guidance updates typically produce moderate short-term effects on valuation and sentiment.
12 May
Lineage Cell Therapeutics, Inc. (LCTX) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates affect financial performance and investor sentiment.
4 May
Lineage Cell Therapeutics presented three-year OpRegen results in geographic atrophy patients at the Foundation Fighting Blindness Retinal Innovation Summit 2026. Three-year clinical data on OpRegen for GA represents a major milestone that could significantly advance pipeline progress and boost investor confidence in LCTX.
31 Mar
Lineage Cell Therapeutics, Inc. (LCTX) launches its latest cell therapy program. Launching a new cell therapy program marks a major strategic pipeline expansion for LCTX with strong potential to drive future growth and investor interest.
24 Mar
Lineage Cell Therapeutics, Inc. (LCTX) launches new cell therapy program targeting corneal endothelial disease, advancing its stem cell platform into a novel therapeutic area. Launching a new cell therapy program expands LCTX's pipeline into corneal endothelial disease, signaling major strategic growth with potential to enhance competitive positioning and investor interest.
6 Mar
Lineage Cell Therapeutics, Inc. (LCTX) released Q4 2025 earnings call summary highlighting financial results, clinical pipeline updates, and strategic outlook. Q4 2025 earnings call summary reveals financial performance and clinical advancements that significantly influence LCTX's trajectory and investor sentiment.
Lineage Cell Therapeutics released Q4 earnings call highlights detailing financial results, clinical pipeline updates, and strategic outlook for the biotech firm. Q4 earnings highlights cover financial performance and pipeline advancements with moderate influence on stock sentiment and trajectory.
5 Mar
Lineage Cell Therapeutics, Inc. (LCTX) reported break-even earnings for the fourth quarter. Break-even Q4 earnings mark a financial milestone that could moderately boost investor sentiment and affect short-term market performance.
Lineage Cell Therapeutics (LCTX) reported fourth quarter and full-year 2025 financial results alongside a business update. Quarterly financial results and business updates provide insights into financial health and operational progress, influencing market sentiment moderately.
6 Jan
Lineage Cell Therapeutics, Inc. has received a gene-edited hypoimmune cell line from Factor Bioscience as part of their partnership. This delivery is expected to enhance Lineage's capabilities in developing cell therapies, potentially advancing their product pipeline and therapeutic offerings. The partnership and delivery of the gene-edited cell line could significantly impact Lineage's product development and market positioning.
Lineage Cell Therapeutics, Inc. (LCTX) is highlighted among three penny stock contenders by NeoVolta, suggesting potential investment opportunities. The article emphasizes the company's innovative approaches in regenerative medicine and its strategic positioning within the biotech sector, which may attract investor interest despite the inherent risks associated with penny stocks. LCTX's innovative strategies in regenerative medicine may moderately influence its market performance and investor sentiment.
5 Jan
Lineage Cell Therapeutics, Inc. has issued a letter to stockholders addressing recent developments and future strategies. The letter outlines the company's commitment to advancing its pipeline and enhancing shareholder value. Key updates include progress in clinical trials and ongoing collaborations aimed at expanding therapeutic applications. The management emphasizes transparency and engagement with investors as they navigate the evolving landscape of cell therapy. The letter indicates a focus on strategic initiatives and clinical advancements that may moderately influence the company's market position.
8 Dec
Lineage Cell Therapeutics, Inc. (LCTX) is highlighted as one of three promising penny stocks with market capitalizations below $800 million. The company focuses on developing innovative cell therapies for various medical conditions, positioning itself as a potential growth opportunity in the biotech sector. Investors are encouraged to consider LCTX for its strategic initiatives and market potential. The company's focus on innovative cell therapies may moderately influence its financial performance and competitive positioning.
7 Nov
Lineage Cell Therapeutics, Inc. (LCTX) reported key highlights from its Q3 2025 earnings call, emphasizing strategic partnerships that are expected to enhance its product pipeline and market position. The company outlined its financial performance, ongoing clinical trials, and future growth strategies, indicating a focus on innovation and collaboration within the biotechnology sector. Strategic partnerships and advancements in clinical trials are likely to significantly impact future performance and investor sentiment.
Lineage Cell Therapeutics held its Q3 2025 earnings call, covering quarterly financial results, clinical pipeline progress for cell therapies, and operational updates. Quarterly earnings call delivers financial results and pipeline status that moderately shape near-term investor sentiment and company valuation.
6 Nov
Lineage Cell Therapeutics, Inc. (LCTX) reported a loss for Q3 but exceeded revenue estimates. The company continues to focus on its innovative cell therapies, which are expected to drive future growth despite the current financial challenges. Investors are closely monitoring the company's strategic initiatives and product developments as they assess its market position. The financial results indicate moderate performance, with potential implications for future product innovation and market sentiment.
Lineage Cell Therapeutics, Inc. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to advance its cell therapy programs, focusing on innovative treatments for various diseases. Financial results indicate a stable cash position, with ongoing investments in research and development. The management expressed optimism about future growth prospects and potential partnerships to enhance product development. The earnings report reflects stable financial health and ongoing R&D efforts, which may moderately influence future performance.
Lineage Cell Therapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting key developments in its business operations. The company provided updates on its ongoing projects and strategic initiatives aimed at advancing its therapeutic pipeline. Financial metrics showed trends that may influence future performance, while management outlined plans for upcoming quarters. The financial results and business updates indicate moderate influences on the company's performance and market positioning.
29 Sep
HC Wainwright has reaffirmed a Buy rating on Lineage Cell Therapeutics, Inc. (LCTX) as the company advances its initiatives in treating Type 1 Diabetes. The firm highlights the potential of Lineage's innovative therapies and their implications for the market, suggesting a positive outlook for the company's future performance. The focus on Type 1 Diabetes represents a significant strategic move that could alter the company's trajectory and investor sentiment.